StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by polo11on Dec 03, 2016 3:02pm

115 Views

Post# 25550911

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:how much will PP be ?

PBAY - I feel generous Today - Will drop my chalenge to three and give you an extra hours; IF SO MANY ....SHOULD BE VERY EASY FOR YOU WHO KNOW EVERYTHING ON SO MANY COMPANY IN EVERY SECTOR.

thepbay wrote: Polo, my point is that with everything in the pipe, and all the expectations GEN has in a very short term, or so they say, they should have been able to get a much higher premium. The broker working the deal set this price so they could sell the proposal. I have seen many debentures where they have gotten above 60% premium. I would have expected something similar here. They got an average deal, nothing to hype up. It is however better that all their previous options. Give to get I guess. GL

pbay

polo11 wrote:
Description

A convertible debenture is an interest bearing, debt obligation which the debenture holder may, at their discretion, exchange for common stock in the company issuing the debenture. The number of shares which the debenture holder is entitled to is based on an exchange ratio that sets the number of common shares that will be received for each debenture held. This is generally expressed as the number of common shares per $1000 (face value) debenture. The terms and conditions applying to convertible debentures are set out in the prospectus and trust indenture. The number of shares which the debenture holder is entitled to receive for each debenture, and the price per share paid by exchanging the debenture for those shares, are set out when the convertible debenture is initially issued.

These term include; the security position generally described as secured, unsecured, senior or subordinated; the maturity date, interest rate, how the debenture is repaid at maturity, i.e. shares and/or cash; and change of control provisions in the event of a takeover. The issuer might also have the right to retract the debentures, usually after a specified date, providing the shares are trading at a premium to the exchange ratio. While the terms for each debenture can vary, it is typical for them to be unsecured and subordinated debt obligations, with maturity dates of 5-10 years. The conversion prices are initially set at between 30-60% of the value of the share price when the convertible debenture is issued.